Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease

Samanta Moroni, Maria Elena Marson, Guillermo Moscatelli, Guido Mastrantonio, Margarita Bisio, Nicolas Gonzalez, Griselda Ballering, Jaime Altcheh, Facundo García-Bournissen, Samanta Moroni, Maria Elena Marson, Guillermo Moscatelli, Guido Mastrantonio, Margarita Bisio, Nicolas Gonzalez, Griselda Ballering, Jaime Altcheh, Facundo García-Bournissen

Abstract

Background: Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available. NF is safe and effective for paediatric and adult Chagas disease. We evaluated the degree of NF transfer into breast milk in lactating women with Chagas disease.

Patients and methods: Prospective study of a cohort of lactating women with Chagas disease. Patients were treated with NF for 1 month. NF was measured in plasma and milk by high performance liquid chromatography (HPLC). Breastfed infants were evaluated at admission, 7th and 30th day of treatment (and monthly thereafter, for 6 months).

Results: Lactating women with chronic Chagas disease (N = 10) were enrolled (median age 28 years, range 17-36). Median NF dose was 9.75 mg/kg/day three times a day (TID). Six mothers had mild adverse drug reactions (ADRs), but no ADRs were observed in any of the breastfed infants. No interruption of breastfeeding was observed. Median NF concentrations were 2.15 mg/L (Inter quartil range (IQR) 1.32-4.55) in milk and 0.30 mg/L (IQR 0.20-0.95) in plasma. Median NF milk/plasma ratio was 16 (range 8.75-30.25). Median relative infant NF dose (assuming a daily breastmilk intake of 150 mL/kg/day) was 6.7% of the maternal dose/kg/day (IQR 2.35-7.19%).

Conclusions: The low concentrations of NF in breast milk and the normal clinical evaluation of the breastfed babies imply that maternal NF treatment for Chagas disease during breastfeeding is unlikely to lead to clinically relevant exposures in the breastfed infants.

Trial registration: Clinical trial registry name and registration number: ClinicalTrials.gov NCT01744405.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Barry MA, Weatherhead JE. Childhood Parasitic Infections Endemic to the United States Chagas Intestinal protozoa Leishmania Childhood Toxoplasma Toxocara. 2013;60:471–485. 10.1016/j.pcl.2012.12.011
    1. Schmunis GA, Yadon ZE. Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop. 2010;115(1–2):14–21. 10.1016/j.actatropica.2009.11.003
    1. Jannin J, Villa L. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz. 2007;102(Suppl. I):95–97. 10.1590/S0074-02762007005000106
    1. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic chagas disease with benznidazole versus no treatment: A nonrandomized trial. Ann Intern Med. 2006;144(10):724–734. 144/10/724 [pii] 10.7326/0003-4819-144-10-200605160-00006
    1. Rocha MOC, Ribeiro AL, Viotti R, et al. A Risk Score for Predicting Death in Chagas’ Heart Disease. N Engl J Med. 2006;355(23):2488–2491. 10.1056/NEJMc062580
    1. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: The role of international migration. In: Memorias Do Instituto Oswaldo Cruz. Vol 102; 2007:75–85. 10.1590/s0074-02762007005000093
    1. Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: Neglected “evidence” by evidence-based medicine. Expert Rev Anti Infect Ther. 2007;5(4):717–726. 10.1586/14787210.5.4.717
    1. Altcheh J, Moscatelli G, Mastrantonio G, et al. Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy despite Lower Plasma Concentrations than in Adults. PLoS Negl Trop Dis. 2014;8(5). 10.1371/journal.pntd.0002907
    1. de Andrade a L, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348(9039):1407–1413. S0140673696041281 [pii] 10.1016/s0140-6736(96)04128-1
    1. Freilij H, Altcheh J. Congenital Chagas’ disease: diagnostic and clinical aspects. Clin Infect Dis. 1995;21(3):551–555. . 10.1093/clinids/21.3.551
    1. Estani SS, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg. 1998;59(4):526–529. 10.4269/ajtmh.1998.59.526
    1. Academy A, Pediatrics OF, Milk H. Breastfeeding and the Use of Human Milk. Pediatr Sect Breastfeed. 2012;129(3):e827–e841. 10.1542/peds.2011-3552
    1. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and Safety of Nifurtimox in Patients with Chronic Chagas Disease. Clin Infect Dis. 2010;51(10):e69–e75. 10.1086/656917
    1. Duffy T, Cura CI, Ramirez JC, et al. Analytical Performance of a Multiplex Real-Time PCR Assay Using TaqMan Probes for Quantification of Trypanosoma cruzi Satellite DNA in Blood Samples. PLoS Negl Trop Dis. 2013;7(1). 10.1371/journal.pntd.0002000
    1. Duffy T, Bisio M, Altcheh J, et al. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis. 2009;3(4). 10.1371/journal.pntd.0000419
    1. Padró JM, Marsón ME, Mastrantonio GE, Altcheh J, García-Bournissen F, Reta M. Development of an ionic liquid-based dispersive liquid-liquid microextraction method for the determination of nifurtimox and benznidazole in human plasma. Talanta. 2013. 10.1016/j.talanta.2012.12.050
    1. Marsón ME, Dana DD, Altcheh J, García-Bournissen F MG. Development of UV/HPLC methods for quantitative analysis of benznidazole in human plasma and urine for application in pediatric clinical studies. J CLIN LAB ANAL. 2013;September;27(5):384–390. 10.1002/jcla.21615
    1. Marson ME, Padró JM, Reta MR, Altcheh J, García-Bournissen F MG. A simple and efficient HPLC method for benznidazole dosage in human breast milk. Ther Drug Monit. 2013;August;35(4):522–6. 10.1097/FTD.0b013e31828f5214
    1. Panchaud A, Garcia-Bournissen F, Csajka C, et al. Prediction of infant drug exposure through breastfeeding: Population PK modeling and simulation of fluoxetine exposure. Clin Pharmacol Ther. 2011;89(6):830–836. 10.1038/clpt.2011.23
    1. Kent JC, Mitoulas L, Cox DB, Owens RA, Hartmann PE. Breast volume and milk production during extended lactation in women. Exp Physiol. 1999;84(2):435–447. 10.1111/j.1469-445X.1999.01808.x
    1. Kent JC. Volume and Frequency of Breastfeedings and Fat Content of Breast Milk Throughout the Day. Pediatrics. 2006;117(3):e387–e395. 10.1542/peds.2005-1417
    1. F. B, Z. C, F. G, et al. Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia. PLoS Negl Trop Dis. 2015;9(2).
    1. Sánchez LV, Ramírez JD. Congenital and oral transmission of American trypanosomiasis: An overview of physiopathogenic aspects. Parasitology. 2013;140(2):147–159. 10.1017/S0031182012001394
    1. García-Bournissen F, Moroni S, Marson ME, et al. Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease. Arch Dis Child. 2015;100(1):90–94. 10.1136/archdischild-2014-306358
    1. Bittencourt AL, Sadigursky M, Da Silva AA, et al. Evaluation of Chagas’ disease transmission through breast-feeding. Mem Inst Oswaldo Cruz. 1988;83(1):37–39. S0074-02761988000100005 [pii]
    1. Campos R, Pinto PL, Moreira AA, Amato Neto V, Duarte MI, de Sant’Ana EJ TG. Experimental study on the transmission of Chagas’ disease by milk. Rev Hosp Clin Fac Med Sao Paulo. 1988;May-Jun;43:146–7.
    1. Ferreira CS, Martinho PC, Amato Neto V, Cruz RR. Pasteurization of human milk to prevent transmission of Chagas disease. Rev Inst Med Trop Sao Paulo. 2001;43:161–162. 10.1590/s0036-46652001000300008
    1. Vela-Bahena LE, Vergara R, Vite L, Ramos C. [Postpartum treatment without interrupting breastfeeding in a patient with Chagas disease]. Ginecol Obstet Mex. 2015.
    1. Garcia-Bournissen F, Altcheh J, Panchaud A, Ito S. Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis. Arch Dis Child. 2010;95(3):224–228. 10.1136/adc.2008.157297
    1. Moscatelli G, Moroni S, García-Bournissen F, et al. Prevention of congenital chagas through treatment of girls and women of childbearing age. Mem Inst Oswaldo Cruz. 2015;110(4):507–509. 10.1590/0074-02760140347
    1. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118–126. 10.1056/NEJM200007133430208
    1. McNamara PJ, Abbassi M. Neonatal exposure to drugs in breast milk. Pharm Res. 2004;21(4):555–566. 10.1023/B:PHAM.0000022401.14710.c5
    1. Rowe H, Baker T, Hale TW. Maternal Medication, Drug Use, and Breastfeeding. Child Adolesc Psychiatr Clin N Am. 2015;24(1):1–20. 10.1016/j.chc.2014.09.005
    1. Olivera MJ, Cucunubá ZM, Álvarez CA, Nicholls RS. Safety profile of nifurtimox and treatment interruption for chronic chagas disease in Colombian adults. Am J Trop Med Hyg. 2015;93(6):1224–1230. 10.4269/ajtmh.15-0256
    1. Watson CP, Dogruel M, Mihoreanu L, et al. The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: Evidence for involvement of breast cancer resistance protein. Brain Res. 2012;1436:111–121. 10.1016/j.brainres.2011.11.053
    1. Sachs HC. The Transfer of Drugs and Therapeutics Into Human Breast Milk: An Update on Selected Topics. Pediatrics. 2013;132(3):e796–e809. 10.1542/peds.2013-1985
    1. Verstegen RHJ, Ito S. Drugs in lactation. J Obstet Gynaecol Res. 2019. 10.1111/jog.13899
    1. Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H. Adverse Events After the Use of Benznidazole in Infants and Children With Chagas Disease. Pediatrics. 2011;127(1):e212–e218. 10.1542/peds.2010-1172
    1. Bianchi F, Cucunubá Z, Guhl F, González NL, Freilij H, Nicholls RS, Ramírez JD, Montilla M, Flórez AC, Rosas F, Saavedra V SN. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia. PLoS Negl Trop Dis. 2015;February 27;9(2.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa